Regenicin to Present at Event Celebrating Advancements in Regenerative Medicine
NEW YORK, Nov. 2, 2010 /PRNewswire/ -- Regenicin, Inc. (OTC Bulletin Board: WDST), a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, will participate in an event to celebrate the newest advancements in regenerative medicine on November 9th, 2010 in Walkersville, MD.
Regenicin will present their role in the commercialization of the therapeutic candidate, PermaDerm™, a product which could help revolutionize the way wounded warriors and civilians recover from severe burns and wounds. Speaking on behalf of Regenicin will be Dr. Craig Eagle, a member of Regenicin's Board of Directors, and head of Oncology for Pfizer Worldwide.
The event will be hosted by Lonza Walkersville, Inc. a subsidiary of Lonza AG, a Swiss based life science company and one of the world's leading cell therapy manufacturers. Also scheduled to participate in the event are the Armed Forces Institute of Regenerative Medicine, the U.S. Department of Defense Office of Technology Transition; as well as members of Congress, U.S. Armed Forces personnel, scientists, firefighters, and surgeons on the frontlines of treating burns and wounds in the U.S.
About PermaDerm™
PermaDerm™ is the only tissue-engineered skin prepared from autologous (patient's own) skin cells from both the epidermal and dermal skin layers. A small sample of the patient's skin can be expanded in the laboratory to cover a wound site that extends over 50% of the patient's body. These self-to-self skin grafts are intended to form permanent wound closure that is not rejected by the patient's immune system, a critical possibility in porcine or cadaver skin grafts used today.
return to 2010 Press and News Releases
return to Home Page
About Regenicin
Regenicin, Inc. (OTC Bulletin Board: RGIN), is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world-class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. The company is publicly traded with headquarters in New Jersey.
Safe Harbor Statement.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: Regenicin(TM), Inc.